This study explored the efficacy and safety of rivaroxaban in elderly patients, at different doses and age of patients, and analyzed risk factors of bleeding. A retrospective analysis was conducted of 299 patients aged 60 years or older who were admitted to the First Hospital of Jilin University between January 2016 and August 2018. It was found that the rate of bleeding events (but not embolism) significantly increased as the dose of oral rivaroxaban increased (P < .001), and with age, especially in patients aged ≥80 years (P = .001, both). The multivariate logistic regression analysis indicated that age (odds ratio [OR]: 2.963, 95% CI: 1.627-5.396) and the daily dose of rivaroxaban (OR: 2.325, 95% CI: 1.483-3.645) were independent risk factors for bleeding. The study determined that rivaroxaban anticoagulant therapy is effective in the elderly patients, but the risk of bleeding increases with age, and is a concern especially in the most old patients. The recommended daily dose of rivaroxaban is effective, but a lower dose is safer for the elderly patients.

本研究探讨了利伐沙班在不同剂量和年龄的老年患者中的疗效和安全性，并分析了出血的危险因素。回顾性分析了2016年1月至2018年8月期间吉林大学第一医院收治的年龄在60岁以上的299位患者。口服利伐沙班增加（P <.001），并且随着年龄的增长，尤其是对于≥80岁的患者（P都等于.001）。多元逻辑回归分析表明，年龄（几率[OR]：2.963，95％CI：1.627-5.396）和利伐沙班的日剂量（OR：2.325，95％CI：1.483-3.645）是出血的独立危险因素。该研究确定利伐沙班抗凝治疗对老年患者有效，但出血风险随年龄增长而增加，尤其是在大多数老年患者中，这是一个值得关注的问题。推荐的利伐沙班每日剂量是有效的，但较低的剂量对老年患者更安全。